by MM360 Staff | Feb 3, 2026 | Publications
Br J Haematol. 2026 Feb 1. doi: 10.1111/bjh.70356. Online ahead of print. NO ABSTRACT PMID:41622574 | DOI:10.1111/bjh.70356
by MM360 Staff | Jan 30, 2026 | Publications
Trop Med Int Health. 2026 Jan 28. doi: 10.1111/tmi.70066. Online ahead of print. ABSTRACT BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) are reported to occur more frequently in Black populations, particularly African...
by MM360 Staff | Jan 29, 2026 | Publications
J Geriatr Oncol. 2026 Jan 26;17(2):102846. doi: 10.1016/j.jgo.2025.102846. Online ahead of print. ABSTRACT INTRODUCTION: Improvements in supportive care strategies and growing evidence for benefit have led to increased use of autologous stem cell transplant (ASCT) in...
by MM360 Staff | Jan 29, 2026 | Publications
Pharmaceuticals (Basel). 2025 Dec 21;19(1):18. doi: 10.3390/ph19010018. ABSTRACT Background: Although anti-CD38 monoclonal antibody-based regimens are standard care for newly diagnosed multiple myeloma (NDMM), direct comparative efficacy and comprehensive real-world...
by MM360 Staff | Jan 29, 2026 | Publications
Front Immunol. 2026 Jan 12;16:1722579. doi: 10.3389/fimmu.2025.1722579. eCollection 2025. ABSTRACT Bispecific antibodies are a novel class of immunotherapies that have demonstrated high response rates in heavily pretreated patients with multiple myeloma. However,...
by MM360 Staff | Jan 23, 2026 | Publications
Front Immunol. 2026 Jan 6;16:1744165. doi: 10.3389/fimmu.2025.1744165. eCollection 2025. ABSTRACT BACKGROUND: The efficacy of CD38 monoclonal antibody (mAb)-based quadruplet regimens versus triplet regimens in newly diagnosed multiple myeloma (NDMM) patients with...
